Posted by Michael Wonder on 05 Jul 2017
Strensiq new deal paves way for NICE approval of life saving drug
5 July 2017 - An agreement has been reached that means more people with a rare life threatening disease can be offered an innovative new medicine.
NICE has published draft guidance recommending the drug asfotase alfa (also called Strensiq and made by Alexion Pharma UK) for people with paediatric-onset hypophosphatasia.
The extremely rare inherited condition affects between 1 and 7 babies each year in England.
A new agreement between the company and NHS England on price and access to the drug means NICE can now widen the group of people eligible for treatment on the NHS.
